BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Treatment of Patients With Acute Sinusitis
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2012-11-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6777
- Registration Number
- NCT00930488
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1b, (Betaseron BAY86-5046)
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 67
- Registration Number
- NCT00928967
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
Phase 4
Completed
- Conditions
- Hemophilia A
- Interventions
- Procedure: No Drug
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 156
- Registration Number
- NCT00927667
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2052
- Registration Number
- NCT00927537
Primovist Regulatory Post Marketing Surveillance (PMS)
Completed
- Conditions
- Liver
- Interventions
- Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4358
- Registration Number
- NCT00924248
Yasmin Post Marketing Surveillance
Completed
- Conditions
- Contraception
- Interventions
- Drug: EE30/DRSP (Yasmin, BAY86-5131)
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 777
- Registration Number
- NCT00923572
Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00922597
US Cycle Control and Blood Pressure Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Gestodene/EE (FC Patch Low, BAY86-5016)Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 346
- Registration Number
- NCT00920985
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT00921245
Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Drug: Cyproterone Acetate (Androcur, BAY94-8367)
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 194
- Registration Number
- NCT00919022
© Copyright 2025. All Rights Reserved by MedPath